Juvenile Arthritis

Tocilizumab May Help Uveitis in Juvenile Idiopathic Arthritis

March 03, 2020

Tocilizumab might be a useful adjunctive therapeutic option for children with juvenile idiopathic arthritis-associated uveitis that doesn't respond to TNFi treatment, say researchers recently writing in The Lancet Rheumatology.

Psoriasis Risk Rises with TNF Inhibitor Use in Pediatric Inflammatory Diseases

November 27, 2019

Children with inflammatory bowel disease, juvenile idiopathic arthritis, and chronic noninfectious osteomyelitis who were treated with TNF inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, say researchers recently writing in Arthritis Care & Research.

JIA Disease Activity Persists, Despite Lower Uveitis, Major Joint Surgery Rates

November 27, 2019

While the need for orthopedic surgery and the presence of uveitis have diminished over the past 20 years in children with juvenile idiopathic arthritis (JIA), disease activity is present more than 50 percent of the time, say researchers recently writing in Arthritis Research and Therapy.

One Step Closer for Macrophage Activation Syndrome Testing in Juvenile Arthritis

November 18, 2019

Researchers reporting at the annual meeting of the American College of Rheumatology earlier this month say they have successfully identified a specific biomarker for macrophage activation syndrome, a complication of childhood rheumatic disease most often affecting children with systemic juvenile idiopathic arthritis.

ACR Annual Meeting Roundup: Higher death rates in lupus

November 14, 2019

In today's slideshow, we highlight the best of the ACR Annual Meeting which wrapped this week in Atlanta. Among the highlights, includes a study that focuses on unusually high death rates in lupus, plus one that suggests new treatments for juvenile idiopathic arthritis are "urgently" needed. Learn more in this slideshow.

Abatacept Monotherapy Effective in JIA

November 10, 2019

ACR Annual Meeting:  Monotherapy with abatacept was safe and effective in patients with polyarticular juvenile idiopathic arthritis who couldn’t tolerate or didn’t respond to methotrexate, researchers reported November 11 at the annual meeting of the American College of Rheumatology in Atlanta.

Rheumatology Nurses Society Meeting Roundup: JIA, a Missed Diagnosis and More

September 13, 2019

From transitioning a pediatric rheumatology patient to adult care to re-evaluating a missed diagnosis, in this slideshow, we highlight some key presentations from the annual Rheumatology Nurses Society meeting held last month. 

Tips for Transitioning a Juvenile Idiopathic Arthritis Patient to Adult Care

September 09, 2019

Better communication between pediatric and adult rheumatologists is especially important as pediatric patients with juvenile idiopathic arthritis transition to adult care.  In this Q&A, we revisit a Rheumatology Nurses Society annual meeting presentation made last month by Cathy Patty-Resk, MSN, RN, CPNP, a pediatric rheumatology nurse practitioner with the Children’s Hospital of Michigan.

Nearly 5% of Children on Biologics Develop Hypersensitivity Reactions, Study Shows

August 21, 2019

Children with active rheumatic disease exposed to multiple biological drugs should be monitored for hypersensitivity reactions, particularly during intravenous infusions, say researchers writing in Pediatric Allergy and Immunology this month

Etanercept Trial Supports Use for JIA, ERA and PsA

June 10, 2019

Etanercept is a safe, well-tolerated medication for treating pediatric patients with extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, and psoriatic arthritis, according to the results for a new study.

x